Cellectis (CLLS) Change in Account Payables (2015 - 2026)
Cellectis (CLLS) recorded quarterly Change in Account Payables of -$3.9 million in Q1 2026, down 856.47% quarter-over-quarter from $510000.0 in Q3 2025, and up 38.65% on a YoY basis from -$2.8 million in Q1 2025.
Cellectis (CLLS) Change in Account Payables (2015 - 2026) Analysis & Trends
Cellectis' Change in Account Payables history runs 12 years deep, the most recent figure standing at -$3.9 million for Q1 2026.
- In Q1 2026, Change in Account Payables rose 38.65% year-over-year to -$3.9 million; the TTM figure through Mar 2026 stood at -$9.6 million (down 682.31% YoY), while the FY2024 annual figure was $2.1 million, up 132.59% from the prior year.
- Change in Account Payables was -$3.9 million for Q1 2026 at Cellectis, down from $510000.0 in the prior quarter.
- In the past five years, Change in Account Payables ranged from a high of $7.3 million in Q2 2022 to a low of -$6.5 million in Q1 2022.
- Historically, Change in Account Payables has averaged -$663562.5 across 5 years, with a median of -$106000.0 in 2024.
- The sharpest annual moves came in 2023 and 2024: Change in Account Payables sank 200.34% in 2023, then jumped 524.47% in 2024.
- A 5-year view of Change in Account Payables shows it stood at $1.8 million in 2022, then tumbled by 200.34% to -$1.8 million in 2023, then surged by 268.13% to $3.0 million in 2024, then plunged by 82.74% to $510000.0 in 2025, then plunged by 856.47% to -$3.9 million in 2026.
- The last three Change in Account Payables figures came in at -$3.9 million (Q1 2026), $510000.0 (Q3 2025), and $23000.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -3.26 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 35.60 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -9.42 Mn |
| 10 | Cellectis | 17.40 Bn | 17.21 Bn | - | -3.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.86 Mn |
| Mar 31, 2026 | -3.86 Mn |
| Sep 30, 2025 | 510,000.00 |
| Sep 30, 2025 | 510,000.00 |
| Jun 30, 2025 | 23,000.00 |
| Jun 30, 2025 | 23,000.00 |
| Mar 31, 2025 | -6.29 Mn |
| Mar 31, 2025 | -6.29 Mn |
| Dec 31, 2024 | 2.95 Mn |
| Dec 31, 2024 | 2.95 Mn |
| Sep 30, 2024 | -235,000.00 |
| Sep 30, 2024 | -235,000.00 |
| Jun 30, 2024 | 5.22 Mn |
| Jun 30, 2024 | 5.22 Mn |
| Mar 31, 2024 | -5.89 Mn |
| Mar 31, 2024 | -5.89 Mn |
| Dec 31, 2023 | -1.76 Mn |
| Dec 31, 2023 | -1.76 Mn |
| Sep 30, 2023 | 2.89 Mn |
| Sep 30, 2023 | 2.89 Mn |